Ruconest: Uses, Dosage & Side Effects
A recombinant human C1 esterase inhibitor used to treat acute attacks of hereditary angioedema (HAE) in adults, adolescents, and children
Ruconest (conestat alfa) is a recombinant human C1 esterase inhibitor (rhC1INH) indicated for the treatment of acute attacks of hereditary angioedema (HAE) in patients with C1 esterase inhibitor deficiency. Hereditary angioedema is a rare genetic disorder characterized by episodes of severe, localized swelling that can affect the skin, gastrointestinal tract, and – most dangerously – the upper airway. Ruconest replaces the missing or dysfunctional C1INH protein, restoring control of the bradykinin-generating pathway that drives HAE attacks. It is administered as a slow intravenous injection either in a healthcare setting or by trained patients and caregivers at home, and it typically begins to relieve symptoms within about 90 minutes. Ruconest is approved in the European Union, the United States, and many other countries as a prescription-only medication.
Quick Facts: Ruconest
Key Takeaways
- Ruconest (conestat alfa) is a recombinant human C1 esterase inhibitor produced in the milk of transgenic rabbits, used to treat acute attacks of hereditary angioedema (HAE) in adults, adolescents, and children aged 2 years and older.
- It works by restoring functional C1INH activity, thereby blocking uncontrolled activation of the contact system and preventing further release of bradykinin – the mediator responsible for the painful swelling, abdominal pain, and potentially life-threatening airway obstruction seen in HAE.
- Ruconest is contraindicated in patients with known or suspected allergy to rabbits or rabbit-derived proteins; rabbit-specific IgE testing is recommended before initiating therapy, and patients should be monitored for hypersensitivity reactions during and after each administration.
- The recommended dose is 50 IU/kg body weight (maximum 4200 IU) as a slow intravenous injection over approximately 5 minutes, administered as early as possible after onset of an attack; most patients experience symptom relief within 1–2 hours.
- Ruconest is approved for on-demand treatment of HAE attacks only – it is not indicated for long-term prophylaxis – and suitable patients can be trained to self-administer the medication at home to reduce time to treatment.
What Is Ruconest and What Is It Used For?
Ruconest contains conestat alfa, a recombinant analogue of human C1 esterase inhibitor (C1INH). The active substance has an amino acid sequence identical to endogenous human C1INH, but it is produced in the mammary glands of transgenic rabbits and then purified from their milk. This biotechnological production method allows large quantities of this complex glycoprotein to be manufactured with high consistency. C1 esterase inhibitor belongs to the family of serine protease inhibitors (serpins) and is one of the key regulators of the complement system, the contact/kinin-generating system, and the intrinsic coagulation cascade.
Hereditary angioedema (HAE) is a rare, autosomal dominant genetic disorder, usually caused by mutations in the SERPING1 gene that encodes C1 esterase inhibitor. In the most common types (Type I and Type II HAE), affected patients have insufficient C1INH activity, which leads to uncontrolled activation of the contact system. This pathway includes factor XII (Hageman factor), prekallikrein, and high-molecular-weight kininogen. In the absence of adequate C1INH regulation, plasma kallikrein cleaves kininogen, releasing bradykinin. Bradykinin acts on the bradykinin B2 receptor on vascular endothelial cells, causing vasodilation, increased vascular permeability, and the characteristic plasma extravasation that produces angioedema attacks.
HAE attacks can involve any part of the body, but the most common sites are the extremities (hands, feet), face, abdomen, genitals, and upper airway. Cutaneous attacks cause disfiguring, often painful swelling that develops over several hours and can last 2 to 5 days without treatment. Abdominal attacks mimic surgical emergencies, producing severe colicky pain, nausea, vomiting, and diarrhea; some patients undergo unnecessary exploratory surgery before HAE is diagnosed. Most dangerously, laryngeal attacks can cause rapid airway obstruction and death if not treated promptly. Without effective therapy, the lifetime risk of death from asphyxiation in untreated HAE is approximately 30–40%.
Ruconest is approved for the treatment of acute angioedema attacks in adults, adolescents, and children aged 2 years and older with hereditary angioedema due to C1 esterase inhibitor deficiency. It is indicated specifically for on-demand (attack-driven) therapy, not for long-term prophylaxis between attacks. By rapidly restoring functional C1INH activity in the circulation, Ruconest halts further bradykinin generation, allowing the already-formed swelling to resolve.
The medication is administered as an intravenous injection over approximately 5 minutes. In pivotal randomized controlled trials, Ruconest significantly shortened the time to beginning of symptom relief (median 90 minutes vs. several hours with placebo) and the time to complete resolution of symptoms. Because early treatment correlates with faster recovery and less morbidity, many patients are trained to self-administer Ruconest at home as soon as an attack begins.
Ruconest is approved by the European Medicines Agency (EMA), the U.S. Food and Drug Administration (FDA), Health Canada, and regulatory authorities in many other countries. It has been granted orphan medicinal product status for HAE because of the rarity of the disease. Ruconest is one of several options for on-demand HAE therapy; alternatives include plasma-derived C1INH concentrates (e.g., Berinert, Cinryze), the bradykinin B2 receptor antagonist icatibant, and the plasma kallikrein inhibitor ecallantide (availability varies by region).
Unlike symptomatic treatments such as antihistamines or corticosteroids – which are ineffective in bradykinin-mediated angioedema – Ruconest directly addresses the underlying cause of HAE attacks by supplementing the deficient C1 inhibitor protein. This mechanistic specificity is why Ruconest and other HAE-specific therapies work quickly in HAE attacks, while conventional allergy medications do not.
What Should You Know Before Receiving Ruconest?
Contraindications
Ruconest must not be used in certain situations. Understanding these absolute contraindications is essential before treatment begins.
- Rabbit allergy: Ruconest is contraindicated in patients with known or suspected allergy to rabbits or rabbit-derived products. Because conestat alfa is produced in the milk of transgenic rabbits, trace amounts of rabbit-derived proteins may be present in the final product and can trigger severe allergic reactions, including anaphylaxis, in sensitized individuals. All patients should be screened with a rabbit dander-specific IgE test before starting therapy, and results must be negative.
- Hypersensitivity: Do not use Ruconest if you have a known hypersensitivity to conestat alfa or to any of the other ingredients in the product (sucrose, sodium citrate, citric acid).
Warnings and Precautions
Serious hypersensitivity reactions, including anaphylaxis, have been reported with Ruconest. Symptoms may include hives, rash, itching, flushing, difficulty breathing, chest tightness, wheezing, swelling of the face or throat, rapid heartbeat, drop in blood pressure, and loss of consciousness. These reactions can occur during or shortly after administration. Ruconest should only be given where appropriate medical supervision and emergency equipment (including epinephrine) are immediately available, and patients who self-administer at home must be trained to recognize and respond to such reactions and seek emergency care.
Before and during treatment with Ruconest, inform your doctor if any of the following apply to you:
- Thromboembolic events: Rare cases of thromboembolic events (blood clots in veins or arteries) have been reported in patients receiving C1 esterase inhibitor products, particularly at higher-than-recommended doses or in patients with pre-existing risk factors. Patients with a history of venous thromboembolism, recent surgery, indwelling catheters, known thrombophilia, or other risk factors should be closely monitored.
- Differential diagnosis of angioedema: Ruconest is indicated only for HAE attacks due to C1 esterase inhibitor deficiency. It is not effective in histamine-mediated angioedema (such as that caused by allergic reactions or some drug-induced angioedema). If there is any doubt about the type of angioedema, specialist consultation is advised. ACE inhibitor-induced angioedema, in particular, is bradykinin-related but responds differently to HAE therapies.
- Laryngeal attacks: Although Ruconest rapidly treats laryngeal angioedema, any patient with airway involvement should be evaluated in a medical facility even after self-administering Ruconest because of the risk of rapid progression and airway obstruction.
- Repeated dosing: If symptoms do not adequately resolve after the first dose, a second dose may be required. Follow the specific dosing guidance from your physician. A second dose typically should not be given less than 2 hours after the first.
- Formation of neutralizing antibodies: As with any recombinant biological product, the development of antibodies against conestat alfa is theoretically possible, though rare in clinical experience. If response to treatment diminishes over time, this should be discussed with your HAE specialist.
Your doctor will assess your overall suitability for Ruconest therapy, including your ability to recognize HAE attacks early and respond appropriately to potential adverse reactions. Home therapy decisions are made on an individual basis.
Other Medications
Tell your doctor about all medications you are currently taking or have recently taken, including prescription medications, over-the-counter products, and herbal supplements. Although formal drug interaction studies with Ruconest are limited, certain medications may influence HAE disease activity or overlap with C1INH therapy.
Pregnancy and Breastfeeding
There is limited clinical experience with Ruconest use during pregnancy. Animal reproduction studies with conestat alfa have not demonstrated direct teratogenic effects. However, because HAE attacks during pregnancy – particularly laryngeal attacks – can be life-threatening for both mother and fetus, treatment decisions must weigh risks against benefits. For acute on-demand treatment of HAE attacks during pregnancy, plasma-derived C1INH concentrate is often preferred by experts due to longer human safety experience, but Ruconest may be considered when alternatives are not available or tolerated.
Tell your doctor before and during treatment if you are pregnant, think you may be pregnant, or are planning to become pregnant. HAE can worsen during pregnancy, and a personalized management plan should be developed with your HAE specialist and obstetrician.
It is not known whether conestat alfa is excreted in human breast milk. Given the large molecular size of C1INH, systemic absorption in a nursing infant is expected to be minimal. However, the decision to use Ruconest while breastfeeding should consider the benefit of therapy to the mother and any potential risk to the infant. Consult your HAE specialist.
Use in Children
Ruconest is approved for children aged 2 years and older with HAE. Pediatric dosing is weight-based and follows the same principles as adult dosing. The safety and effectiveness of Ruconest in children under 2 years of age have not been established, and the product is not recommended for this age group outside of clinical trial settings. Pediatric HAE management is best coordinated by specialists experienced in this rare disease.
Use in Elderly Patients
Clinical trials of Ruconest have included a limited number of patients aged 65 years and older. No overall differences in safety or effectiveness have been identified between older and younger patients, but greater sensitivity of some older individuals cannot be ruled out. Dosing should remain weight-based, but attention should be paid to comorbid conditions such as cardiovascular disease, renal impairment, and increased thromboembolic risk.
Driving and Operating Machinery
No studies have been conducted on the effects of Ruconest on the ability to drive or use machines. Dizziness has been reported in some patients following administration. Additionally, an untreated or partially treated HAE attack may itself impair driving ability. Patients should not drive if they are experiencing an ongoing attack or have recently received emergency treatment.
Important Information About Ingredients
Ruconest contains sodium (19.5 mg per vial of 2100 IU, equivalent to approximately 1% of the WHO-recommended maximum daily sodium intake for adults). This should be considered in patients on a strict sodium-restricted diet. The product also contains sucrose as an excipient – patients with rare hereditary problems of fructose intolerance or sucrase-isomaltase insufficiency should discuss this with their doctor before use.
How Does Ruconest Interact with Other Drugs?
Interactions between Ruconest and other medicines have not been extensively studied in dedicated pharmacokinetic trials. Because conestat alfa is a large protein eliminated through endocytosis and degradation rather than via the cytochrome P450 enzyme system, it is not expected to cause classical hepatic drug interactions. However, certain combinations warrant attention due to pharmacodynamic considerations and shared biological pathways.
Major Interactions
| Interacting Drug | Effect | Clinical Significance |
|---|---|---|
| Tissue plasminogen activator (tPA, alteplase) | Theoretical risk of altered fibrinolysis; case reports of reduced response to tPA in stroke patients with elevated C1INH | Inform all treating physicians; use with caution in acute ischemic stroke or myocardial infarction |
| ACE inhibitors (e.g., enalapril, lisinopril, ramipril) | ACE inhibitors prevent bradykinin breakdown, potentially triggering or worsening angioedema attacks in HAE | Strongly avoided in HAE patients; alternative antihypertensives should be used |
| Estrogen-containing contraceptives and hormone replacement therapy | Estrogen can trigger or worsen HAE attacks by increasing factor XII and bradykinin generation | Estrogen-containing products are generally avoided; progestin-only alternatives preferred |
| Other C1INH products or HAE therapies (icatibant, ecallantide, plasma-derived C1INH) | No direct interaction but overlapping pharmacology | Sequential use is possible under specialist guidance if initial therapy is inadequate |
Other Relevant Medications
| Interacting Drug | Effect | Clinical Significance |
|---|---|---|
| Attenuated androgens (danazol, stanozolol) | Used for long-term HAE prophylaxis in some patients; no direct Ruconest interaction | Ruconest can be used for acute attacks even in patients on androgen prophylaxis |
| Tranexamic acid | Antifibrinolytic used for long-term prophylaxis in HAE; no direct Ruconest interaction | Can be combined in a comprehensive HAE management plan |
| Lanadelumab (plasma kallikrein inhibitor) | Used for long-term HAE prophylaxis; no pharmacokinetic interaction | Ruconest remains an option for breakthrough attacks in patients on lanadelumab |
| Berotralstat (oral plasma kallikrein inhibitor) | Used for long-term prophylaxis | Ruconest can be used for on-demand therapy even while on berotralstat |
| Anticoagulants (warfarin, DOACs) | No direct interaction; thrombosis risk assessment required | Monitor for thromboembolic events, especially at higher C1INH doses |
The HAE treatment landscape has evolved significantly, with multiple on-demand and prophylactic options now available. Your HAE specialist will coordinate your overall treatment plan, balancing attack frequency, severity, triggers, and patient preferences. Always carry a written treatment plan and information card listing your HAE diagnosis and current medications, so that emergency personnel can respond appropriately if you cannot communicate.
What Is the Correct Dosage of Ruconest?
Ruconest is always administered intravenously. Patients suitable for home therapy receive training from a specialist centre before self-administering. Each vial contains 2100 IU of lyophilised conestat alfa and must be reconstituted with 14 mL of sterile water for injection immediately before use. The resulting solution contains approximately 150 IU/mL. Dosing is individualised based on body weight and clinical response.
Adults
Adults Weighing Less Than 84 kg
Dose: 50 IU per kg body weight, administered as a single slow intravenous injection over approximately 5 minutes
Example: A 70 kg adult would receive 3500 IU (approximately 23 mL of reconstituted solution)
Onset of relief: Median time to beginning of symptom relief is approximately 90 minutes in clinical trials
Adults Weighing 84 kg or More
Dose: 4200 IU (two vials) as a single slow intravenous injection over approximately 5 minutes – this is the maximum recommended dose per treatment
Rationale: Clinical studies have established that doses above 4200 IU do not provide additional benefit and may increase the theoretical risk of thromboembolic events
Children and Adolescents (2 to 17 years)
Children Weighing Less Than 84 kg
Dose: 50 IU per kg body weight as a single slow intravenous injection over approximately 5 minutes
Indications: Treatment of acute HAE attacks in pediatric patients aged 2 years and older with documented C1 esterase inhibitor deficiency
Pediatric HAE management should be coordinated by specialists experienced in managing this rare disease in children.
Adolescents Weighing 84 kg or More
Dose: 4200 IU (two vials) as a single slow intravenous injection over approximately 5 minutes
As in adults, doses above 4200 IU have not demonstrated additional benefit.
Elderly Patients
No specific dose adjustment is required based on age alone. Ruconest dosing in patients 65 years and older follows the standard weight-based approach of 50 IU/kg up to a maximum of 4200 IU. Greater attention may be appropriate for elderly patients with cardiovascular comorbidities or an increased risk of thromboembolic events.
Patients with Renal or Hepatic Impairment
No dedicated studies have been conducted in patients with renal or hepatic impairment. Because conestat alfa is a large protein cleared primarily through endocytosis and proteolytic degradation, significant accumulation in organ dysfunction is not expected. No specific dose adjustment is recommended, but patients with significant comorbid disease should be monitored closely.
Repeat Dosing
If symptoms of an HAE attack do not begin to resolve within a reasonable timeframe after the first dose, or if they worsen, a second dose of Ruconest may be administered under medical supervision. Typically, a second dose should not be given sooner than 2 hours after the first. The maximum cumulative dose within 24 hours should not exceed 4200 IU unless specifically directed by your HAE specialist based on individual clinical circumstances. Persistent or worsening attacks despite treatment warrant urgent medical evaluation, especially if the airway is involved.
Missed Dose
Because Ruconest is used on-demand to treat acute HAE attacks rather than as scheduled maintenance therapy, the concept of a "missed dose" does not apply in the traditional sense. However, delaying treatment during an active attack has been shown to prolong symptoms and worsen outcomes. If you experience an HAE attack, administer Ruconest (or the medication prescribed for your attack) as early as possible. If you are uncertain whether symptoms represent an HAE attack, contact your HAE specialist for guidance.
Overdose
Clinical experience with doses above the recommended 50 IU/kg (maximum 4200 IU) is limited. At high doses of C1 esterase inhibitor products, rare thromboembolic events have been reported, including deep vein thrombosis, pulmonary embolism, stroke, and myocardial infarction, particularly in patients with pre-existing risk factors. In the event of suspected overdose, patients should be closely monitored for signs of thromboembolism and given supportive care. Contact a poison control centre or emergency department for advice.
How Ruconest Is Given
Ruconest is supplied as a white to off-white lyophilised powder in a glass vial, accompanied by a vial of water for injection for reconstitution. Each 2100 IU vial is reconstituted with 14 mL of sterile water, resulting in a solution containing approximately 150 IU/mL. The reconstituted solution should be clear and colourless to slightly yellow; do not use if discoloured or containing particulate matter.
The required dose is drawn up into a syringe and administered as a slow intravenous injection over approximately 5 minutes. Ruconest is not given as a continuous infusion. Injection into a peripheral vein is typically adequate. Patients self-administering at home must be trained in aseptic technique, venous access, and recognition of adverse reactions.
Home therapy with Ruconest allows patients to treat HAE attacks promptly, reducing attack severity and duration. However, home therapy requires thorough training from a specialist centre, including instruction in reconstitution, venous access, slow IV injection technique, and management of hypersensitivity reactions. All patients using home therapy should have a written action plan and know when to seek emergency medical care, especially for airway involvement.
What Are the Side Effects of Ruconest?
Like all medicines, Ruconest can cause side effects, although not everyone gets them. Side effects may occur during injection, shortly afterward, or hours later. Because Ruconest is usually given for on-demand treatment of an HAE attack, it can sometimes be difficult to distinguish medication side effects from symptoms of the attack itself. Your healthcare team will help interpret what you are experiencing.
Hypersensitivity and Anaphylaxis
As a recombinant protein produced in transgenic rabbits, Ruconest carries a risk of hypersensitivity reactions, especially in patients sensitised to rabbit proteins. Rabbit allergy is an absolute contraindication to Ruconest therapy. Even in patients who pre-screen negative, rare hypersensitivity reactions including anaphylaxis have been reported. Warning symptoms include hives, itching, flushing, facial or throat swelling, difficulty breathing, wheezing, chest tightness, rapid heartbeat, and lightheadedness. Severe reactions can progress rapidly; emergency epinephrine should be available wherever Ruconest is administered.
Side Effects by Frequency
Very Common
May affect more than 1 in 10 people
- Headache
Common
May affect up to 1 in 10 people
- Nausea
- Dizziness
- Paresthesia (tingling, prickling, or “pins and needles” sensation)
- Throat irritation or dry throat
- Diarrhea or abdominal discomfort
- Fatigue or general feeling of being unwell (malaise)
Uncommon
May affect up to 1 in 100 people
- Hypersensitivity reactions (rash, itching, urticaria, angioedema unrelated to HAE attack)
- Swelling of extremities (peripheral edema)
- Ear discomfort or pain
- Oropharyngeal pain or sore throat
- Vertigo
- Skin reactions such as flushing or erythema
- Abdominal distension
- Tingling or numbness in localized areas
Rare
May affect up to 1 in 1000 people
- Anaphylaxis (severe systemic allergic reaction)
- Thromboembolic events (blood clots in veins or arteries) – typically in association with higher doses or pre-existing risk factors
- Severe infusion-related reactions including bronchospasm or hypotension
Not Known
Frequency cannot be estimated from available data
- Formation of antibodies against conestat alfa (no conclusive impact on efficacy or safety in long-term experience)
- Local injection-site reactions such as bruising, redness, or transient pain
When to Seek Emergency Care
Sudden difficulty breathing, rapid progression of throat swelling, severe facial swelling, generalized hives with dizziness or fainting, severe chest pain, one-sided weakness, slurred speech, severe headache with vomiting, or sudden severe leg pain or swelling. These may indicate anaphylaxis, airway compromise, or a thromboembolic event requiring urgent medical intervention.
Reporting Side Effects
If you experience any side effects, including those not listed here, tell your doctor, pharmacist, or nurse. You can also report suspected side effects directly to your national pharmacovigilance authority – such as the European Medicines Agency (EMA), the U.S. FDA MedWatch programme, or the UK Medicines and Healthcare products Regulatory Agency (MHRA) Yellow Card Scheme. Reporting suspected adverse reactions helps authorities continuously monitor the benefit-risk balance of Ruconest and other medicines.
How Should Ruconest Be Stored?
Correct storage ensures that Ruconest retains full potency and safety. Storage conditions may vary slightly between regions based on local marketing authorisations, so always follow the specific instructions on your product label and package leaflet.
- Unopened vials: Store below 25°C (77°F) in the original outer carton to protect from light. Do not freeze.
- Shelf life: Do not use Ruconest after the expiry date (EXP) printed on the vial label and outer carton. The expiry date refers to the last day of the month indicated.
- Reconstituted solution: Should be used immediately after preparation. If immediate use is not possible, the reconstituted solution may typically be stored at room temperature for up to 8 hours, provided reconstitution was performed under aseptic conditions. Do not refrigerate or freeze the reconstituted solution.
- Visual inspection: The reconstituted solution should be clear and colourless to slightly yellowish. Do not use if the solution is cloudy, contains particulate matter, or has changed colour.
- Travel: Ruconest can be transported at ambient temperatures, which is an advantage compared with some biologics that require cold-chain storage. Nevertheless, temperatures above 25°C should be avoided for prolonged periods.
- Disposal: Do not dispose of medicines via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. These measures help protect the environment.
If you are enrolled in home therapy, your specialist centre will advise on how many vials to keep on hand and how to rotate stock to ensure you always have unexpired product available for an attack. For travel, carry Ruconest in hand luggage with supporting medical documentation to avoid delays at security checkpoints.
What Does Ruconest Contain?
Active Substance
The active substance is conestat alfa, a recombinant analogue of human C1 esterase inhibitor. Each vial of powder contains 2100 international units (IU) of conestat alfa. After reconstitution with 14 mL of sterile water for injection, each mL contains approximately 150 IU of conestat alfa. One IU is defined according to the European Pharmacopoeia reference standard for functional C1INH activity.
Conestat alfa is produced by recombinant DNA technology in the mammary glands of transgenic New Zealand White rabbits that carry the human gene for C1 esterase inhibitor. The protein is isolated from the rabbits’ milk and highly purified. Although its amino acid sequence is identical to human C1INH, the glycosylation pattern differs slightly from plasma-derived C1INH due to the different expression system. This difference in glycans contributes to the shorter plasma half-life of conestat alfa compared with plasma-derived C1INH.
Inactive Ingredients (Excipients)
The lyophilised powder contains the following excipients:
- Sucrose
- Sodium citrate
- Citric acid
The accompanying solvent is sterile water for injection.
Appearance and Packaging
Ruconest is presented as a white to off-white lyophilised cake or powder supplied in a clear glass vial sealed with a rubber stopper and aluminium crimp cap. Each pack contains one vial of Ruconest 2100 IU powder, one vial containing 14 mL of water for injection for reconstitution, and the package leaflet. Depending on regional regulations, a transfer device may also be included.
Non-Human Origin and Orphan Status
Because conestat alfa is produced in transgenic rabbits rather than human plasma, Ruconest avoids the theoretical risks of blood-borne pathogen transmission associated with plasma-derived C1INH products. This may be an important consideration for some patients. However, the product cannot be used in individuals with rabbit allergy. Ruconest is designated as an orphan medicinal product for the treatment of hereditary angioedema in multiple jurisdictions, reflecting the rarity of the disease.
Marketing Authorisation Holder and Manufacturer
Ruconest is developed and marketed by Pharming Technologies B.V. (the Netherlands) with commercial distribution partners in various territories. The marketing authorisation holder and country-specific importer information can be found on the product labelling and package leaflet.
Frequently Asked Questions About Ruconest
Ruconest (conestat alfa) is used to treat acute attacks of hereditary angioedema (HAE) in adults, adolescents, and children aged 2 years and older. HAE is a rare genetic disorder caused by deficiency or dysfunction of C1 esterase inhibitor, leading to episodes of severe localized swelling that can affect the skin, extremities, abdomen, and airway. Ruconest restores functional C1INH activity in the bloodstream, stopping further bradykinin release and allowing the swelling to resolve. It is indicated only for on-demand (attack-driven) treatment, not for long-term prophylaxis.
Ruconest begins to relieve symptoms relatively quickly after intravenous injection. In pivotal randomized controlled trials, the median time to beginning of symptom relief was approximately 90 minutes (1.5 hours), compared with several hours on placebo. Most patients experience meaningful symptom improvement within 2 to 4 hours, and complete resolution may occur within 8 to 24 hours depending on the attack severity and site. Because early treatment correlates with faster recovery, Ruconest should be administered as soon as possible after attack onset.
No. Ruconest is absolutely contraindicated in patients with known or suspected allergy to rabbits or rabbit-derived proteins. Because conestat alfa is produced in the milk of transgenic rabbits, trace amounts of rabbit-derived proteins may be present and can trigger severe allergic reactions, including anaphylaxis. All patients should be screened with a rabbit dander-specific IgE blood test before starting therapy, and the result must be negative. If you have a rabbit allergy, your HAE specialist will prescribe an alternative on-demand treatment, such as plasma-derived C1 inhibitor, icatibant, or ecallantide (where available).
Yes, Ruconest can be self-administered at home by properly trained adults and caregivers. Home therapy is preferred by many patients because it allows immediate treatment at the first sign of an attack, which shortens attack duration and reduces the need for emergency care. Patients must receive structured training from a specialist centre on reconstitution, venous access, slow IV injection, aseptic technique, and recognition and management of hypersensitivity reactions. Each home-therapy patient should have a written HAE action plan and clear criteria for seeking emergency medical care, especially if an attack involves the airway.
Clinical experience with Ruconest during pregnancy is limited. Animal studies have not demonstrated direct harmful effects on pregnancy or fetal development. Because untreated HAE attacks, particularly laryngeal ones, can be life-threatening, treatment should not be withheld when medically necessary, but plasma-derived C1 inhibitor concentrate is often preferred during pregnancy due to longer human safety experience. Ruconest is considered an option when other therapies are unsuitable. It is not known whether conestat alfa passes into breast milk, although systemic absorption by a nursing infant is expected to be minimal. Discuss pregnancy, breastfeeding, and family planning with your HAE specialist.
Both Ruconest and plasma-derived C1 inhibitor products (such as Berinert and Cinryze) replace functional C1 esterase inhibitor activity in HAE patients. The main differences are the source and pharmacokinetics. Ruconest is a recombinant protein produced in transgenic rabbits, avoiding the theoretical risk of blood-borne pathogen transmission from human plasma. It has a shorter plasma half-life (approximately 2.4–2.7 hours) than plasma-derived products (approximately 30–60 hours for functional C1INH activity), due to different glycosylation. This shorter half-life does not appear to compromise efficacy for acute attack treatment but does make Ruconest less suitable for routine long-term prophylaxis. Choice of therapy is individualised based on patient preference, rabbit allergy status, attack frequency, and clinical response.
Ruconest is licensed specifically for hereditary angioedema due to C1 esterase inhibitor deficiency. It is not approved for ACE inhibitor-induced angioedema or for histamine-mediated (allergic) angioedema. ACE inhibitor-induced angioedema, although bradykinin-mediated, has a different pathogenesis and response profile; some clinicians use HAE therapies off-label in severe cases, but the evidence is limited. Allergic angioedema is driven by histamine and responds to antihistamines, corticosteroids, and epinephrine – not to C1 inhibitor therapy. Establishing the correct type of angioedema is essential before considering Ruconest.
References
- European Medicines Agency (EMA). Ruconest (conestat alfa) – Summary of Product Characteristics. Last updated 2025. Available from: EMA EPAR.
- U.S. Food and Drug Administration (FDA). Ruconest (C1 Esterase Inhibitor [Recombinant]) Prescribing Information. Revised 2024. Available from: FDA Drug Label.
- Maurer M, Magerl M, Betschel S, et al. The international WAO/EAACI guideline for the management of hereditary angioedema—The 2021 revision and update. Allergy. 2022;77(7):1961–1990. doi:10.1111/all.15214.
- Busse PJ, Christiansen SC, Riedl MA, et al. US HAEA Medical Advisory Board 2020 Guidelines for the Management of Hereditary Angioedema. J Allergy Clin Immunol Pract. 2021;9(1):132–150. doi:10.1016/j.jaip.2020.08.046.
- Zuraw BL, Cicardi M, Levy RJ, et al. Recombinant human C1-inhibitor for the treatment of acute angioedema attacks in patients with hereditary angioedema. J Allergy Clin Immunol. 2010;126(4):821–827.e14. doi:10.1016/j.jaci.2010.07.021.
- Riedl MA, Bernstein JA, Li H, et al. Recombinant human C1-esterase inhibitor relieves symptoms of hereditary angioedema attacks: phase 3, randomized, placebo-controlled trial. Ann Allergy Asthma Immunol. 2014;112(2):163–169.e1. doi:10.1016/j.anai.2013.12.004.
- Farkas H, Reshef A, Aberer W, et al. Treatment effect and safety of icatibant, ecallantide, and recombinant human C1 inhibitor for acute attacks of hereditary angioedema in paediatric patients. Pediatr Allergy Immunol. 2017;28(6):574–581.
- Longhurst H, Cicardi M, Craig T, et al. Prevention of hereditary angioedema attacks with a subcutaneous C1 inhibitor. N Engl J Med. 2017;376(12):1131–1140. doi:10.1056/NEJMoa1613627.
- World Health Organization (WHO). International Nonproprietary Names (INN) for Biological and Biotechnological Substances – Conestat alfa. Geneva: WHO; 2023.
- Bork K, Hardt J, Witzke G. Fatal laryngeal attacks and mortality in hereditary angioedema due to C1-INH deficiency. J Allergy Clin Immunol. 2012;130(3):692–697. doi:10.1016/j.jaci.2012.05.055.
- Cicardi M, Aberer W, Banerji A, et al. Classification, diagnosis, and approach to treatment for angioedema: consensus report from the Hereditary Angioedema International Working Group. Allergy. 2014;69(5):602–616. doi:10.1111/all.12380.
- British National Formulary (BNF). Conestat alfa monograph. London: BMJ Group and Pharmaceutical Press; 2025.
Editorial Team
This article was written and reviewed by the iMedic Medical Editorial Team, comprising licensed specialist physicians with expertise in clinical immunology, allergy, rare diseases, and clinical pharmacology.
Medical Content
iMedic Immunology Editorial Team – specialist physicians in clinical immunology and allergy with experience in rare disease management and HAE care
Medical Review
iMedic Medical Review Board – independent panel verifying accuracy against EMA SmPC, FDA label, and WAO/EAACI HAE guidelines
Pharmacology Review
iMedic Clinical Pharmacology Team – specialists in biologics, drug interactions, pharmacokinetics, and medication safety
Accessibility & SEO
iMedic Digital Health Team – ensuring WCAG 2.2 AAA compliance and optimal search visibility
All content follows the GRADE evidence framework and is reviewed according to international medical guidelines. iMedic receives no commercial funding from pharmaceutical companies.